CSL Behring

From Wikipedia, the free encyclopedia
Jump to: navigation, search

CSL Behring is one of the world's leading plasma protein biotherapeutics companies. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures a range of plasma-derived and recombinant therapies worldwide. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[1]

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.[2]

CSL Behring LLC
Headquarters King of Prussia, Pennsylvania
Key people Paul Perreault, CEO and Managing Director of CSL Limited
Employees 11,000+[3]
Website http://www.cslbehring.com/

Company Statistics[edit]

Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia
Headquarters: King of Prussia, PA
Employees: 11,000+[4]
Operations: In 27 countries
CEO and Managing Director: Paul Perreault[5]
R&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia.

History[edit]

CSL Behring is a member of the CSL Group of companies. Parent company CSL Limited (ASX: CSL) is a specialty biopharmaceutical company headquartered in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company has a long history dating back to 1904.[6]

CSL Behring traces its heritage back to Emil von Behring, the inventor of serum therapy or serology.

1901: Emil von Behring was the first recipient of the Nobel Prize in Physiology or Medicine.[7]

1904: Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines.

1913: Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.

1916: CSL (then Commonwealth Serum Laboratories) was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand.

1917: CSL produces 3 million doses of a mixed bacterial vacine to combat the 1919 influenza pandemic.

1930: CSL releases its first life-saving antivenom for tiger snake bites.

1940: Armour Pharmaceuticals (a predecessor company) in Kankakee, Illinois, becomes the largest supplier of human albumin (the most abundant protein in human blood plasma) in World War II.

1944: CSL begins producing penicillin on a large scale for the military and Australia is the first country to supply the drug to civilians at no charge.

1949: ZLB (Zentrallaboratorium Blutspendedienst, a predecessor company) is established in Bern, Switzerland, as a department of the Swiss Red Cross and holds its first donor blood sessions in Switzerland.

1954: Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL.

1966: Rh(D) immunoglobulin, produced from plasma, is introduced by CSL for haemolytic disease in newborns.

1981: Behringwerke introduces Haemate® human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A.

1991: CSL Limited is incorporated in Australia.

2000: ZLB Bioplasma (a predecessor company) is established, acquiring the plasma fractionation assets from SRK, a nonprofit organization affiliated with the Swiss Red Cross. ZLB becomes the fifth largest manufacturer of plasma products worldwide.

2001: Aventis Behring (a predecessor company) acquires 42 plasma centers, forming the world's largest plasma collection business.

2004: CSL Limited completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).

2007: ZLB Behring becomes CSL Behring.

2009: ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens the world's largest and most advanced plasma testing laboratories in Knoxville, Tennessee.

2009: National Organization for Rare Disorders (NORD) recognized CSL Behring for developing and marketing the first and only treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.

2009: CSL Behring awarded the Swiss government's Tell Award for exceptional innovations in state-of-the-art manufacturing and novel protein therapies.

2012: The European Organisation for Rare Disorders recognized CSL Behring for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.


[8]

Products[edit]

CSL Behring researches, develops, manufactures and markets a range of plasma-derived and recombinant products and related services, specializing in the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies; hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[1]

Immunology:

Coagulation/Bleeding Disorders:

Pulmonary:

  • Zemaira®, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)

Critical Care:

  • Beriplex® P/N, Kcentra™, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan® P, RiaSTAP™, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin® P, freeze-dried human antithrombin III concentrate
  • AlbuRx®, Alburex, Human Albumin Behring, Albuminar®, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert® P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Streptase®, freeze-dried streptokinase

Wound Healing:

(Note: Product availability varies from country to country, depending on registration status.)

[9]

Offices[edit]

The company is headquartered in King of Prussia, Pennsylvania.[10] It has 11,000+ employees in 27 countries.[11] Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany, Kankakee, Illinois, and Broadmeadows, Australia.[12]

External links[edit]

References[edit]